Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
Date:3/5/2009

SAN DIEGO, March 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2008 financial results after the market closes on Thursday, March 12, 2009.

Cadence management will host a conference call and live webcast to discuss the financial results and provide a clinical program update on Thursday, March 12, 2009 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Interested investors may participate in the conference call by dialing 877-681-3371 (domestic) or 719-325-4846 (international). To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals,
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
2. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
8. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
9. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... DNA Genotek, a leading provider of products for...t Tepnel Pharmaceutical Services will offer Oragen...ucleic acid extraction and genotyping service. , ...r 1, 2009 -- DNA Genotek , a leading provider of ...nnounced that Tepnel Pharmaceutical Services wil...
(Date:12/1/2009)... The two humanitarian organizations will collabo... biomedical repair technologies. Their shared effo... country of Togo. , Dalla...signing of a Memorandum of Understanding, Mercy Sh...artnership to help develop sustainable infrastruct...
(Date:12/1/2009)... California waste-to-energy firm claims first pl...eration, smallest footprint, salable pure gas, byp... (PRWEB) December 15, 2009 -- The ...tive organic waste-to-energy process will take pla...uary. , , ,This biowaste process known as VRAD&co...
(Date:11/30/2009)...Ohio, Nov. 30 The Ohio Capital Fun...ion,s first minority business early-stage capital ...ber 3, is called "Transforming the Landscape of Bu... Capital Summit." It will feature several speakers...eaders and local minority entrepreneurs. ,, "T...
Breaking Biology Technology:Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 2Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 3Mercy Ships and MediSend International Partner to Deliver Hope and Healing 2Mercy Ships and MediSend International Partner to Deliver Hope and Healing 3First Public Showing of Innovative Waste-to-Energy Process 2Ohio Capital Fund Announces Sponsorship of Minority Business Conference 2
...Jersey, December 5, Rosetta Genomics, Ltd. (NASDAQ...pany leveraging microRNAs as biomarkers,reported t...arter ended,September 30, 2008 and business highli...e third quarter of 2008 of $705,000.,These revenue...rkway Clinical,Laboratories at the end of July thr...
...c.,(Nasdaq: MDVN ) today announced that David Hu...ill be a featured speaker on two panels at the RBC...rsday, December 11, in New York: , -- "Wagin...tern Time, -- "The Challenge of Alzheimer,s Dis... A live audio webcast of each panel will be ...
... 4 Octapharma,Chairman Wolfgang Marguerre today a...o lead Octapharma,s plasma operations in the Unite...counsel since 2002 and will now serve as,President...ivate plasma products company in the world, Octaph...nta company that operates 12,plasma centers in the...
Other Biology Technology:Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 2Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 3Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 4Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 5Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 6Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 7Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 8Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 9Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 10Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference 2Octapharma Names Dennis D. Curtin To Lead U.S. Plasma Operations 2
(Date:11/30/2009)...roteins are crucial for infection. Each binds a sp...ch stimulates the host cell to take up the pathoge...erent function, for example the regulation of cell...e now been published in the current issue of the "...is one of the sources for Listeria infections le...
(Date:11/30/2009)...stress of seeing your extended family over the hol...ch report in the December 2009 print issue of the ...io.org ) shows that you might be right. Here,s the... to entirely new treatments that help keep autoimm...er control. That,s because researchers from the Un...
(Date:11/26/2009)...me of the Ocean,s most distinctive residents. ,Eve...ge head shape, says Michelle McComb from Florida ...ark,s vision. ,Perhaps their visual field has been... giving the sharks excellent stereovision and dept...were two schools of thought on this theory. In 194...
Breaking Biology News(10 mins):It takes 2 to infect 2Seeing family for the holidays? Scientists discover how the stress might kill you 2Wide heads give hammerheads exceptional stereo view 2The Chopra Center Press Set to Release New Book this June 25 49801 1The Chopra Center Press Set to Release New Book this June 25 49801 2The Chopra Center Press Set to Release New Book this June 25 49801 3A Canada wide technology platform for mapping the human interactome 8974 1A Canada wide technology platform for mapping the human interactome 8974 2Video 3A Gabrielle Reece Shows Natural is Beautiful in New PureVia 28TM 29 Campaign 49795 1Video 3A Gabrielle Reece Shows Natural is Beautiful in New PureVia 28TM 29 Campaign 49795 2Video 3A Gabrielle Reece Shows Natural is Beautiful in New PureVia 28TM 29 Campaign 49795 3
...Researchers at New York University,s Courant Insti... algorithm that enhances the ability to detect a c...p the set of tumor-suppressor genes involved in lu...,s gene-chips that can scan hundreds of patients, ...he findings will appear in the July issue of the A...
...Knee cartilage injuries can be effectively repaire...t stop the regeneration process concludes research... The study, "Maturation of tissue engineered carti... knees", published in the July 2006 (Volume 12, Nu...that engineered cartilage tissue can grow and matu...
...Bacteria like Salmonella have a complicated immune...ign DNA trying to invade their cell membrane, acco...he June 8 issue of Science Express. The research, ...l Cancer Center in San Diego, could have major imp...se-causing bacteria. The findings may also impact ...
Other Biology News:NYU algorithm enhances ability to detect cancer genes 2NYU algorithm enhances ability to detect cancer genes 3Bacteria have their own immune system protecting against outside DNA 2
Sheep Anti-Human Vesicle Associated Membrane Protein (VAMP 1/2) Polyclonal Antibody, Unconjugated from Exalpha Biologicals, Inc.
Rat Anti-Mouse TCR, Va 2 Monoclonal Antibody, Unconjugated, Clone B20.1 from CEDARLANE Laboratories Limited
Feline IFN-alpha, Unconjugated from R&D Systems
...A Development kit contains the basic components re...easure natural and recombinant canine Monocyte Che...tes and serum.1 Each kit contains sufficient mater...l plates, provided that the following conditions a...
Biology Products: